N-terminal Pro-Brain Natriuretic Peptide Levels Predict Left Ventricular Systolic Function in Patients with Chronic Kidney Disease by Lee, Jung Eun et al.
INTRODUCTION
It is estimated that more than 10% of adults have chronic
kidney disease (CKD), and its prevalence is gradually increas-
ing (1). Patients with chronic kidney disease are at increased
risk of cardiovascular death (2). Left ventricular (LV) systolic
dysfunction is a common terminal pathway for a variety of
heart diseases. The presence of LV systolic dysfunction is asso-
ciated with high morbidity and mortality in CKD patients
(3). However, LV systolic dysfunction is difficult to identify
based solely on the clinical history and physical examination,
because neither is specific nor sensitive (4, 5). Although echocar-
diography is the current “gold standard” for evaluation of car-
diac dysfunction (3), it is expensive and not always readily
available.
Recently, brain natriuretic peptide (BNP) and N-terminal
pro-brain natriuretic peptide (NT-proBNP) have been exten-
sively studied as useful biochemical markers of ventricular
dysfunction and heart failure in the general population (5-8).
The kidney appears to play an important role in the clearance
of NT-proBNP. Several studies have demonstrated that im-
paired renal function increases NT-proBNP levels, indepen-
dent of ventricular function (9, 10). Therefore, diagnostic value
of NT-proBNP to predict LV systolic function in patients with
significant renal impairment remains unclear. Moreover, poten-
tial cut points of NT-proBNP to detect LV systolic dysfunc-
tion in patients with CKD has not been systematically eval-
uated. For these reasons, we undertook this study to evaluate
whether NT-proBNP levels could predict ventricular dysfunc-
tion in patients with established CKD.
MATERIALS AND METHODS
Patients
We enrolled retrospectively adult patients with CKD who
visited the outpatient clinic of the Department of Nephrology
or the emergency room between March 2003 and March 2005
on whom we performed both NT-proBNP measurement and
echocardiography. We excluded patients undergoing dialysis
or those with a glomerular filtration rate (GFR) greater 60
mL/min/1.73 m2. A total of 274 patients were identified. We
then excluded 18 patients who were finally diagnosed as hav-
ing pulmonary diseases such as pulmonary thromboembolism
or pneumonia. This left a final set of 256 patients to be ana-
lyzed. The causes of CKD were diabetic nephropathy (155
patients), hypertensive nephrosclerosis (34 patients), chronic
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N-terminal Pro-Brain Natriuretic Peptide Levels Predict Left Ventricular
Systolic Function in Patients with Chronic Kidney Disease
N-terminal pro-brain natriuretic peptide (NT-proBNP) can be a useful marker for left
ventricular (LV) dysfunction in patients without kidney disease. This study was con-
ducted to clarify the relationship between NT-proBNP and LV systolic function in pa-
tients with decreased renal function. We studied 256 chronic kidney disease (CKD)
patients, patients on dialysis were excluded. The median glomerular filtration rate
was 24 (13-36) mL/min/1.73 m
2 and the median NT-proBNP was 4,849 (1,310-
19,009) pg/mL. The prevalence of LV systolic dysfunction increased from the lower
to the upper NT-proBNP quartiles (I, 17%; II, 34%; III, 61%; and IV, 72%; p<0.001
for trend). The NT-proBNP quartile was an independent predictor of LV systolic dys-
function after adjustment for renal function, compared with quartile I: II, odds ratio
(OR) 3.99 (95% confidence interval [CI],1.34-11.93); III, OR 11.28 (95% CI, 3.74-33.95);
and IV, OR 36.97 (95% CI, 11.47-119.1). Area under the curve and optimum cut
points for NT-proBNP to detect LV systolic dysfunction were 0.781 and 2,165 pg/mL
in CKD stage 3, 0.812 and 4,740 pg/mL in CKD stage 4, and 0.745 and 15,892 pg/
mL in CKD stage 5. The NT-proBNP level was a predictor of LV systolic dysfunction
in CKD patients. Optimum cut points should be stratified according to renal function.
Key Words : Biological Markers; Kidney Failure, Chronic; Ventricular Dysfunction, Left; Pro-brain Natriuretic
Peptide (1-76)
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Accepted : 17 December 2008glomerulonephritis (25 patients), autosomal dominant poly-
cystic kidney disease (five patients), other causes (four patients)
and unknown causes (33 patients). 78 patients were enrolled
in outpatient clinics and others were enrolled in emergency
room.
Clinical variables
Patients’ demographic and clinical information were obtained
by chart review. A diagnosis of diabetes, hypertension, and
coronary artery disease (CAD) were included if they were iden-
tified in the patient’s history and/or by physical examination.
CAD was defined as documented myocardial infarction, coro-
nary artery bypass graft surgery, or percutaneous coronary inter-
vention. The GFR was estimated using the abbreviated Mod-
ification of Diet in Renal Disease formula (1). Each estimat-
ed GFR was categorized into one of three groups as less than
15 mL/min/1.73 m2 (CKD stage 5), 15-29 mL/min/1.73 m2
(CKD stage 4), and 30-59 mL/min/1.73 m2(CKD stage 3) (1).
Echocardiographic measurement and definition
Echocardiography was performed as per our standard lab-
oratory protocol by one of five expert sonographers. Findings
were analyzed to quantify LV ejection fraction (EF) and LV
mass. LV mass was determined by using the formula of Dev-
ereux et al. (11) which was adjusted for height. Left ventric-
ular hypertrophy (LVH) was considered to be present when
the LV mass index was greater than two standard deviations
above the mean of the respective gender control group. The
EF was calculated by the Simpson method, using end-dias-
tolic volume and end-systolic volume measurements. LV sys-
tolic dysfunction was defined as an LV EF of 50% or less.
Assay for NT-proBNP
Blood samples were drawn routinely in lithium heparin
tubes and centrifuged at 1,000 g for 12 min. The plasma was
used for measurement of NT-proBNP using a commercially
available immunoassay (Elecsys proBNP; Roche Diagnostic
Corp, Indianapolis, IN, U.S.A.) on an Elecsys 1,010 analyz-
er according to the manufacturer’s directions. The measur-
able range of the NT-proBNP assay was up to 35,000 pg/mL.
Statistical analysis
Data for continuous variables were expressed as median and
interquartile ranges. Categorical variables were expressed as
absolute numbers and percentages. Comparisons between three
or more data groups were analyzed by a nonparametric (Krus-
kal-Wallis) test for continuous variables and by a likelihood
ratio test for trends for categorical variables. To assess the inde-
pendent contribution to LV systolic dysfunction, we used logis-
tic regression. A p value of less than 0.05 was considered to
be statistically significant. Separate receiver operating char-
acteristic (ROC) curves were generated for NT-proBNP and
detection of LV systolic dysfunction, as a function of GFR
categories. All statistical analyses for this study were conduct-
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Values expressed as median (interquartile range). Categorical data expressed as number (percent). 
*We could not assess information regarding these variables in some patients (less than 10% of the study patients). Thus, the sums of numbers given
do not equal 256.
NYHA, New York Heart Association; LE, lower extremity; GFR, glomerular filtration rate; LV MI, left ventricular mass index; LV EF, left ventricular ejection
fraction; LVH, left ventricular hypertrophy; NT- proBNP, N-terminal pro-brain natriuretic peptide.
Variables
Quartile I Quartile II Quartile III Quartile IV
p
(40-1,303 pg/mL) (1,331-4,773 pg/mL) (4,925-18,392 pg/mL) (19,215-35,000 pg/mL)
No of Patients 64 64 64 64 -
Age (yr) 65 (58-73) 67 (54-77) 67 (61-73) 63 (53-74) NS
Men 39 (61%) 40 (63%) 40 (63%) 30 (47%) NS
*NYHA class O or I/II/III/IV 42/5/10/3  31/11/15/2 20/7/18/15 14/8/14/18 <0.001
*Orthopnea (yes/no) 9/52 8/52 17/40 29/30 <0.001
*LE edema (yes/no) 10/52 15/44 25/37 37/24 <0.001
Diabetes 34 (53%) 31 (48%) 36 (56%) 46 (72%) 0.004
Hypertension 45 (70%) 43 (67%) 48 (75%) 49 (77%) 0.036
Coronary artery disease 9 (14%) 21 (33%) 26 (41%) 20 (31%) <0.001
Hemoglobin (g/dL) 10.3 (9.0-12.0) 9.6 (8.4-11.2) 10.8 (9.3-12.4) 9.3 (8.4-10.7) 0.012
GFR (mL/min/1.73 m
2) 30 (20-43) 25 (16-37) 22 (13-38) 18 (9-28) <0.001
CKD stage 3/4/5 32/21/11 23/27/14 21/23/20 11/22/31 <0.001
LV MI (gm/m
2) 148 (118-178) 146 (114-175) 169 (144-202) 181 (154-221) <0.001
LV EF (%) 62 (55-68) 58 (44-67) 45 (30-58) 40 (34-52) <0.001
*LVH (yes/no) 34/20 41/19 53/7 52/9 <0.001
LV EF <40% 2 (3%) 14 (22%) 27 (42%) 33 (52%) <0.001
LV EF <50% 11 (17%) 22 (34%) 39 (61%) 46 (72%) <0.001
Table 1. Clinical characteristics and echocardiographic findings according to NT-proBNP quartilesed with SPSS 11.0 for Windows.
RESULTS
The demographics of the study patients were as follows. The
median age was 66 (58-74) yr. There were 149 men and 107
women. The most prominent symptoms were shortness of
breath in 111 patients, chest discomfort in 45 patients, periph-
eral edema in 18 patients, and other symptoms in 59 patients.
Twenty-three patients were asymptomatic. The median GFR
was 24 (13-36) mL/min/1.73 m2 and the median NT-proB-
NP level was 4,849 (1,310-19,009) pg/mL. LVH was present
in 77% of the patients and 118 (46%) had LV systolic dys-
function. Clinical and echocardiographic findings stratified
by NT-proBNP quartiles are listed in Table 1. Patients in
the upper NT-proBNP quartiles showed higher New York
Heart Association function classes. Orthopnea and lower ex-
tremity edema were observed more often in patients in upper
NT-proBNP quartiles. Diabetes, hypertension, and CAD were
also more prevalent in the upper NT-proBNP quartiles. Medi-
an estimated GFR and median LV EF decreased from the lower
to the upper NT-proBNP quartiles. The prevalence of LV sys-
tolic dysfunction increased from 17% in the lowest quartile
to 72% in the highest quartile.
We classified patients by CKD stage, with 87 (34%) patients
with CKD stage 3, 93 (36%) with CKD stage 4, and 76 (30%)
with CKD stage 5. Table 2 shows clinical and echocardio-
graphic findings according to CKD stages. Orthopnea and
lower extremity edema were observed more often in patients
with advanced stage of CKD.
Fig. 1 shows median NT-proBNP levels according to LV
systolic function and CKD stage. The median NT-proBNP
level increased progressively with lower LV EF in each CKD
stages (all p<0.001 for trend). Also the median NT-proBNP
level increased from CKD stage 3 to stage 5 in each LV EF
groups (all p<0.001 for trend). Of note is that CKD stage 5
patients with normal LV systolic function had NT-proBNP
levels similar to those in CKD stage 3 patients with LV EF
of less than 40% (8,859 [1,672-21,831] pg/mL vs. 8,026
[2,605-17,994] pg/mL).
Multiple logistic regression analyses were performed to deter-
mine whether the NT-proBNP level could independently pre-
dict the presence of LV systolic dysfunction. The NT-proB-
NP quartile was found to be an independent predictor of LV
systolic dysfunction after adjustment for age, gender, CAD,
diabetes, hypertension, GFR, hemoglobin levels, and LVH.
The odds ratio of having LV systolic dysfunction increased
NT-proBNP and LV Systolic Function in CKD S65
Variables CKD stage 3 CKD stage 4 CKD stage 5 p
No of Patients 87 93 76
*NYHA class
O or I/II/III/IV 50/10/20/7 25/6/24/15 32/15/13/16 0.005
*Orthopnea (yes/no) 14/73 22/53 27/48 0.001
*LE edema (yes/no) 19/68 29/56 39/33 0.001
*LVH (yes/no) 51/21 64/23 65/11 0.001
LV EF <50% 45 (52%) 46 (50%) 27 (36%) 0.042
Data expressed as number (percent). 
*We could not assess information regarding these variables in some
patients. Thus, the sums of numbers given do not equal 256.
NYHA, New York Heart Association; LE, lower extremity; LVH, left ven-
tricular hypertrophy; LV EF, left ventricular ejection fraction.
Table 2. Clinical characteristics and echocardiographic findings
according to CKD stages
LV EF <50% LV EF <40%
Odds ratio (95% CI) p Odds ratio (95% CI) p
NT-proBNP  
Quartile I 1 1
Quartile II 3.99 (1.34-11.93) 0.013 28.08 (2.63-299.1) 0.006
Quartile III 11.28 (3.74-33.95) <0.001 56.39 (5.58-569.5) 0.001
Quartile IV 36.97 (11.47-119.1) <0.001 256.6 (22.57-2915) <0.001
These models also included age, gender, coronary artery disease, diabetes, hypertension, glomerular filtration rate, hemoglobin, and left ventricular
hypertrophy.
LV EF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide.
Table 3. Multiple logistic regression models-association between NT-proBNP quartiles and LV systolic function
Fig. 1. Median NT-proBNP level according to left ventricular systolic
function and CKD stage (p<0.01 for both inter-CKD stages and inter-
LV EF groups). 
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LVEF >50%progressively in the higher NT-proBNP quartiles. Patients
in the highest quartile had nearly 37-fold increased odds of
having LV systolic dysfunction, compared with those in the
lowest quartile (odds ratio 36.97; 95% CI, 11.47 to 119.1).
The NT-proBNP quartile was also an independent predic-
tor of having an LV EF less than 40%.
ROC curves for NT-proBNP to detect LV systolic dysfunc-
tion (LV EF ≤50%), and for each of the CKD stages, are pre-
sented in Fig. 2A. AUC and optimum cut points were 0.781
and 2,165 pg/mL, 0.812 and 4,740 pg/mL, and 0.745 and
15,892 pg/mL in patients with CKD stage 3, 4, and 5. Using
these levels, the sensitivity and specificity of NT-proBNP were
73% and 69%, 76% and 77%, and 74% and 74% in CKD
stage 3, 4, and 5, respectively. AUC to detect severe LV sys-
tolic dysfunction (LV EF ≤40%) were 0.780, 0.793, and
0.802 for CKD stage 3, 4, and 5, respectively (Fig. 2B). Opti-
mum cut points for NT-proBNP increased progressively with
CKD stage.
DISCUSSION
This study demonstrates that NT-proBNP was an indepen-
dent predictor of LV systolic dysfunction in patients with
established CKD. Although NT-proBNP level was increased
with decreasing GFR, the NT-proBNP level was negatively
associated with LV EF independent of renal dysfunction. Opti-
mum cut points of NT-proBNP to detect LV systolic dysfunc-
tion were much higher in CKD patients than those reported
in the general population and these were increased progres-
sively with lower renal function. These results suggest that
even in patients with advanced renal dysfunction, the mea-
surement of NT-proBNP level might be of benefit in predict-
ing LV systolic function in the setting of suspected heart fail-
ure and that the NT-proBNP level should be interpreted along
with values for renal function in order to predict LV systolic
dysfunction. If cut points without adjustment for renal func-
tion are applied, the usefulness of NT-proBNP levels is lim-
ited in CKD patients.
The diagnostic and prognostic roles of NT-proBNP have
been well established in a variety of cardiac diseases (9, 10,
12-15). Most investigators have excluded CKD patients from
their studies because of potentially elevated levels of the pep-
tide (9, 10, 12-15). However, an easily measurable biomarker
for cardiac disease is sorely needed in CKD patients, because
symptoms mimicking congestive heart failure occur very often
among them (3). Our study suggests that NT-proBNP mea-
surement might be used as a screening tool in CKD patients
with clinically suspected LV systolic dysfunction. Compared
with patients in the lowest NT-proBNP quartile, patients in
the upper quartiles had an increased probability of LV systolic
dysfunction, based on multivariate analysis.
Previous studies investigating the clinical implications of
NT-proBNP measurement in CKD patients showed that NT-
proBNP quartile were associated with LVH and coronary artery
disease in stable pre-ESRD patients (16-19). In our current
study, the prevalence of LVH increased in the higher NT-proB-
NP quartiles. However, after adjustment for the GFR, levels
of NT-proBNP alone could not predict the presence of LVH
(data not shown). A thickened LV wall might lead to an in-
creased secretion of NT-proBNP in CKD patients, just as in
subjects without kidney disease (11). We presume that the
effect of LVH on the NT-proBNP level was much smaller than
the effect of impaired renal function or LV systolic dysfunc-
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Fig. 2. Receiver operating characteristic curves for NT-proBNP to detect LV EF ≤50% (A) and LV EF ≤40% (B) in each stages of CKD.
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7,387 pg/mLtion. Accordingly, NT-proBNP was not an independent pre-
dictor of LVH in our patients with a high prevalence of LV
systolic dysfunction and advanced renal dysfunction. Previ-
ous studies showed lower prevalence of LV systolic function
than our study and the relation between LV systolic function
and NT-proBNP levels were not evaluated systemically. Alt-
hough a few studies have shown that NT-proBNP level was
associated with LV systolic function in CKD patients, inde-
pendent association were not evaluated (20, 21).
It is well established that impaired renal function is asso-
ciated with an elevated NT-proBNP level (9, 10, 14, 18). The
NT-proBNP level is likely to increase corresponding to the
severity of renal dysfunction by several possible mechanisms.
Decreased renal clearance may play a role, at least in part (22).
Concomitant anemia and cardiac overload may contribute to
an increase in the NT-proBNP level in CKD patients, in the
same manner as for the BNP level (22). Elevated NT-proB-
NP may also reflect silent myocardial infarction, LVH or dias-
tolic dysfunction (18, 23).
The high prevalence of LV dysfunction seen in our study
is noteworthy. There were 46% of patients with LV systolic
dysfunction and 77% of patients with LVH. Higher preva-
lence of LV systolic dysfunction than in previous studies on
CKD patients (16-18) could be explained that we included
patients who need emergent treatment and most patients were
symptomatic. 
Several limitations apply to this study. First, we did not
consider volume status or silent myocardial ischemia. Both
might be associated with NT-proBNP levels in CKD patients.
However, it is difficult to evaluate the exact volume status
or assess silent myocardial ischemia based solely on clinical
findings. Second, the NT-proBNP assay used in the study has
an upper limit of 35,000 pg/mL. 14% of our study patients
had a NT-proBNP level equal or greater to this. Therefore,
we could not analyze direct correlations of the NT-proBNP
level with GFR or LVEF. Instead, we stratified by quartiles
to analyze the relationship between NT-proBNP levels and
LV systolic function. Third, the fact that our study patients
were relatively old limits the generalizability of our finding
in the whole CKD patients. Fourth, GFRs estimated using
the abbreviated MDRD study equation were used to classi-
fy CKD stages. Although, the MDRD study equation has
been used widely in large epidemiologic studies and in clin-
ical practice, it has not been validated for the Korean popu-
lation.
In summary, although the NT-proBNP level is increased
in the majority of patients with renal dysfunction, higher NT-
proBNP levels were associated with a higher prevalence of
LV systolic dysfunction, independent of renal function. The
measurement of NT-proBNP levels might be of benefit in
the prediction of LV systolic function in CKD patients with
suspected congestive heart failure. However, renal function
must be taken into consideration when NT-proBNP mea-
surement is used as a diagnostic tool. A prospective study is
needed to determine the diagnostic value and optimal cut-
off levels for NT-proBNP for predicting LV dysfunction in
CKD patients.
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